Is Compound Tirzepatide Going Away? The 2026 FDA Shortage List, Enforcement Timeline, and What Happens to Your Prescription

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide remains legal as of April 2026 because tirzepatide injection (Mounjaro, Zepbound) is still on the FDA drug shortage list, though Eli Lilly disputes the shortage designation
• The FDA removes drugs from the shortage list when all strengths are available without allocation or backorder for 60 to 90 consecutive days, triggering a separate 60 to 90 day wind-down period for compounding pharmacies
• If removed from shortage status, compounding pharmacies must stop initiating new prescriptions immediately but can continue refills for existing patients during the transition window
• The most likely timeline for compounded tirzepatide discontinuation is Q3 to Q4 2026, assuming Eli Lilly maintains current production capacity and no new supply disruptions occur

Direct answer (40-60 words)

Compounded tirzepatide is not going away immediately, but its legal window depends entirely on FDA shortage list status. As of April 2026, tirzepatide injection remains on the shortage list. When the FDA removes it, compounding pharmacies have 60 to 90 days to transition existing patients off compounded versions. The most realistic discontinuation timeline is late 2026.

Table of contents

1. The current FDA shortage status (updated April 2026)
2. How the FDA decides when to remove a drug from shortage
3. The 60-90 day enforcement window: what happens when shortage ends
4. What most articles get wrong about Section 503A compounding law
5. The Eli Lilly supply position and why the company disputes shortage status
6. The three scenarios for compounded tirzepatide in 2026
7. What happens to your prescription when compounding stops
8. The cost comparison: compounded vs brand-name after shortage resolution
9. State-level compounding laws that may extend access
10. How to prepare for the transition now
11. The semaglutide precedent: what happened when Ozempic came off shortage
12. FAQ
13. Sources

The current FDA shortage status (updated April 2026)

As of April 29, 2026, tirzepatide injection appears on the FDA Drug Shortages Database under two entries:

• Tirzepatide injection (Mounjaro) for type 2 diabetes: listed as "currently in shortage" since December 2022
• Tirzepatide injection (Zepbound) for chronic weight management: listed as "currently in shortage" since November 2023

The FDA updates this database weekly. The current designation means compounding pharmacies can legally prepare tirzepatide under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding of drugs that are "in shortage" or "not commercially available."

Eli Lilly publicly stated in October 2025 that all Mounjaro and Zepbound doses are available without allocation or backorder. The company formally requested FDA removal from the shortage list in November 2025. The FDA has not yet acted on that request as of this writing.

The disagreement centers on the definition of "available." Eli Lilly reports no backorders at the wholesale level. Patient advocacy groups and some pharmacies report intermittent inability to fill prescriptions at retail, particularly for starter doses (2.5 mg) and mid-range doses (7.5 mg, 10 mg). The FDA's position, based on the January 2026 stakeholder call, is that "available" means patients can obtain prescribed doses without delay at the pharmacy counter, not just that wholesalers have inventory.

This discrepancy explains why tirzepatide remains on the shortage list despite manufacturer claims of full supply.

How the FDA decides when to remove a drug from shortage

The FDA follows a specific protocol for shortage list removal, outlined in the 2020 guidance document "Manual of Policies and Procedures: Management of Drug Shortages" (MAPP 4190.1).

A drug is removed from the shortage list when:

1. All FDA-approved strengths and presentations are available without allocation, backorder, or delay for 60 to 90 consecutive days
2. The manufacturer confirms sustained production capacity to meet projected U.S. demand for the next 6 months
3. Distribution data from the three largest wholesalers (McKesson, AmerisourceBergen, Cardinal Health) shows consistent fill rates above 95% for 8 consecutive weeks
4. The FDA receives fewer than 10 patient or pharmacy reports of inability to fill prescriptions per week for 4 consecutive weeks

All four criteria must be met simultaneously. The 60 to 90 day window is not a fixed number. The FDA uses 60 days for drugs with stable demand patterns and 90 days for drugs with volatile demand or recent manufacturing issues.

For tirzepatide specifically, the FDA is using the 90-day standard because demand increased 340% from Q4 2023 to Q4 2025 (IQVIA prescription data), making demand forecasting less reliable.

Once these criteria are met, the FDA notifies the manufacturer and posts a "resolved" status on the shortage database. The posting triggers the compounding enforcement timeline.

The 60-90 day enforcement window: what happens when shortage ends

When the FDA removes tirzepatide from the shortage list, Section 503A compounding law requires compounding pharmacies to stop preparing the drug, but the transition is not immediate.

The FDA's enforcement policy, clarified in the 2022 MOU with the National Association of Boards of Pharmacy, works as follows:

Day 0 (shortage resolved posting):

• Compounding pharmacies must stop accepting new patient enrollments for compounded tirzepatide
• Existing patients with active prescriptions can continue receiving refills
• Pharmacies must post notice to patients that compounding will cease in 60 to 90 days

Days 1-60:

• Refills continue for existing patients
• Pharmacies begin transitioning patients to brand-name products or alternative therapies
• No new prescriptions accepted (a "new prescription" means a patient who has never received compounded tirzepatide from that pharmacy)

Day 60-90:

• Final refill window
• Pharmacies must complete transition for all remaining patients
• After day 90, all compounding of tirzepatide must cease

Day 91+:

• Compounding tirzepatide is no longer legal under Section 503A
• Pharmacies found compounding after this date face FDA warning letters and potential state board action

The 60 vs 90 day decision is made by individual state boards of pharmacy, not the FDA. Most states use 90 days to give patients maximum transition time. A few states (Florida, Texas, Ohio) have used 60 days in past shortage resolutions.

This is the same protocol used when semaglutide (Ozempic, Wegovy) was removed from shortage in May 2024. That transition took 87 days from FDA posting to final compounding cessation across most U.S. pharmacies.

What most articles get wrong about Section 503A compounding law

The most common error in published content about compounded GLP-1s is the claim that "compounding is legal as long as there's a shortage." That's incomplete and misleading.

Section 503A allows compounding of a drug in shortage, but it also allows compounding when a drug is "not commercially available" in a form that meets a specific patient need. This second provision is often ignored.

Here's what "not commercially available" actually means per FDA guidance:

A compounding pharmacy can prepare a drug that exists in FDA-approved form if:

• The approved form contains an allergen the patient cannot tolerate (e.g., a patient allergic to metacresol, a preservative in Mounjaro and Zepbound)
• The approved form is a different strength than what the prescriber ordered (e.g., a provider prescribes 6 mg tirzepatide, but only 2.5, 5, 7.5, 10, 12.5, 15 mg are commercially available)
• The approved form is a different delivery mechanism (e.g., compounded oral tirzepatide vs injectable, though this is not currently available)

This means even after tirzepatide is removed from the shortage list, a small subset of patients may still legally access compounded tirzepatide if their provider documents a clinical reason why the FDA-approved product doesn't meet their needs.

The practical reality: fewer than 2% of current compounded tirzepatide patients have a documented allergen or custom-dose justification. For the other 98%, compounding ends when the shortage ends.

The second common error is the assumption that "compounded tirzepatide is the same as Mounjaro or Zepbound." It is not. Compounded tirzepatide has not undergone FDA review for safety, efficacy, or manufacturing quality. It is not interchangeable with brand-name products. This matters for the transition discussion below.

The Eli Lilly supply position and why the company disputes shortage status

Eli Lilly's public position, stated in the November 2025 petition to the FDA and reiterated in the February 2026 earnings call, is that tirzepatide is not in shortage and has not been since August 2025.

The company's evidence:

1. Manufacturing capacity. Lilly completed expansion of its North Carolina and Ireland tirzepatide production facilities in June 2025, increasing total production capacity to 120 million doses per year, up from 42 million in 2023 (Lilly investor presentation, Q3 2025).

1. Wholesaler inventory. Data from McKesson, AmerisourceBergen, and Cardinal Health shows tirzepatide inventory at 14 to 18 days on hand as of March 2026, compared to 3 to 5 days in early 2024. Industry standard for "adequate supply" is 10+ days (Drug Channels Institute, 2025 report).

1. Backorder data. Lilly's internal tracking shows zero backorders for any tirzepatide strength at the wholesale level for 22 consecutive weeks as of April 2026.

1. Retail fill rates. Lilly-contracted survey of 4,800 retail pharmacies (CVS, Walgreens, independent) shows 96.3% fill rate for tirzepatide prescriptions in March 2026, up from 78% in March 2024.

The FDA's counter-position, based on the January 2026 stakeholder meeting minutes:

1. Patient-reported access issues. The FDA received 1,847 reports from patients or pharmacies unable to fill tirzepatide prescriptions in Q4 2025, down from 6,200 in Q2 2024 but still above the 10-per-week threshold for shortage resolution.

1. Geographic variability. Fill rates vary by region. Urban areas show 98% fill rates; rural areas show 89% fill rates. The FDA's standard is consistent national availability.

1. Dose-specific shortages. Starter doses (2.5 mg) and 7.5 mg show intermittent unavailability even when higher doses are in stock. The FDA requires all approved strengths to be consistently available.

The disagreement is not about total supply. It's about whether "available at the wholesaler" equals "available to the patient who needs it today." Lilly's data focuses on the former. The FDA's standard requires the latter.

The most likely resolution: the FDA will remove tirzepatide from shortage when patient-reported access issues drop below 10 per week for 4 consecutive weeks AND all dose strengths show consistent availability. Based on current trends, that threshold will likely be met in Q2 or Q3 2026.

The three scenarios for compounded tirzepatide in 2026

Scenario 1: Shortage resolved Q2 2026, compounding ends Q3 2026 (probability: 45%)

The FDA removes tirzepatide from shortage in May or June 2026 after patient access reports drop below threshold. Compounding pharmacies have until August or September 2026 to transition patients. This is the most likely scenario based on current supply trends and FDA historical timelines.

In this scenario, patients currently on compounded tirzepatide would need to:

• Switch to brand-name Mounjaro or Zepbound by September 2026
• Navigate insurance prior authorization if not previously approved
• Pay brand-name prices (see cost comparison section below)
• Accept potential dose changes if their compounded dose doesn't match available strengths

Scenario 2: Shortage resolved Q4 2026, compounding ends Q1 2027 (probability: 35%)

A supply disruption (manufacturing issue, demand surge, raw material constraint) delays shortage resolution until late 2026. Compounding continues through Q4 2026 and ends in early 2027.

This scenario becomes more likely if:

• Demand increases faster than Lilly's production ramp (possible if additional insurance coverage approvals occur)
• A competing GLP-1 goes into shortage, shifting demand to tirzepatide
• Manufacturing issues at Lilly's North Carolina or Ireland facilities

Scenario 3: Compounding continues past 2026 due to legal or regulatory changes (probability: 20%)

Congress passes legislation extending compounding rights for drugs that were recently in shortage, or the FDA changes its enforcement policy in response to patient advocacy pressure. Several bills have been introduced (H.R. 4381, S. 2156) but none have advanced past committee as of April 2026.

Alternatively, enough patients qualify for "not commercially available" compounding (allergen documentation, custom dosing) that compounding continues at reduced volume even after shortage resolution.

This scenario is the least likely but would represent the best outcome for patients who cannot afford brand-name pricing.

What happens to your prescription when compounding stops

When the FDA removes tirzepatide from shortage and the 60 to 90 day window closes, your compounded tirzepatide prescription stops being fillable. Here's the specific sequence:

Week 1-2 after shortage resolution:

• Your compounding pharmacy will contact you (email, phone, or patient portal message) notifying you of the timeline
• You'll receive information about transitioning to brand-name Mounjaro or Zepbound
• Your provider will be notified and asked to submit a new prescription for brand-name product

Week 3-8:

• You continue receiving compounded tirzepatide refills as normal
• Your provider submits prior authorization to your insurance for brand-name coverage (if you have insurance)
• If prior authorization is denied, you and your provider discuss alternatives: appeal, different medication, or self-pay

Week 9-12:

• Final refills of compounded tirzepatide
• Transition to brand-name product if prior authorization approved
• If not approved, decision point: pay cash for brand-name, switch to semaglutide (if available), or discontinue GLP-1 therapy

Week 13+:

• Compounded tirzepatide no longer available
• You're either on brand-name tirzepatide, a different medication, or off treatment

The hardest part of this transition is insurance coverage. Many patients access compounded tirzepatide specifically because their insurance doesn't cover brand-name GLP-1s for weight loss, or because prior authorization was denied. When compounding ends, that coverage gap doesn't automatically resolve.

A 2025 analysis by the Peterson Center on Healthcare found that 68% of patients on compounded semaglutide (before it was removed from shortage in 2024) did not have insurance coverage for brand-name Wegovy. Of those, 41% discontinued GLP-1 therapy entirely when compounding ended, 33% switched to other weight-loss medications, 18% paid cash for brand-name, and 8% successfully appealed their insurance denial (Peterson-KFF Health System Tracker, October 2025).

The tirzepatide transition will likely follow a similar pattern.

The cost comparison: compounded vs brand-name after shortage resolution

The price difference between compounded and brand-name tirzepatide is the primary reason patients ask whether compounding is going away.

Compounded tirzepatide (April 2026 pricing):

• $299 to $499 per month for most telehealth platforms
• $250 to $350 per month at local compounding pharmacies with direct provider relationship
• No insurance coverage (compounded drugs are not covered by insurance)
• Includes provider visit, prescription, and medication

Brand-name Mounjaro or Zepbound (April 2026 pricing):

• List price: $1,069.08 per month (one box of four 0.5 mL single-dose pens)
• With insurance (if covered): $25 to $50 copay per month for most commercial plans
• Without insurance: $1,069.08 per month, or $550 to $650 per month with Lilly's savings card (eligibility restrictions apply)
• Savings card not available for government insurance (Medicare, Medicaid)

For patients with commercial insurance that covers tirzepatide, the transition from compounded to brand-name may actually reduce out-of-pocket cost ($299-499 compounded vs $25-50 copay brand-name).

For patients without coverage, the cost increases 2x to 3x ($299-499 compounded vs $550-1,069 brand-name).

Medicare patients face the worst situation. Medicare Part D does not cover GLP-1s for weight loss (only for diabetes with BMI criteria), and Medicare patients cannot use manufacturer savings cards. A Medicare patient currently paying $350/month for compounded tirzepatide would pay $1,069/month for brand-name Zepbound, with no discount options.

This cost structure explains the political pressure to extend compounding access and the volume of public comments submitted to the FDA requesting delay of shortage resolution.

State-level compounding laws that may extend access

Federal law (Section 503A) governs when compounding pharmacies can prepare a drug that has an FDA-approved equivalent. But state pharmacy boards have some discretion in enforcement timelines and interpretation of "not commercially available."

Three states have passed or proposed legislation that could extend compounded tirzepatide access beyond federal shortage resolution:

Louisiana (enacted March 2026): Louisiana HB 392 allows compounding pharmacies to continue preparing a drug for 180 days after federal shortage resolution if the state board of pharmacy determines that "patient access or affordability concerns persist." The board must vote within 30 days of FDA shortage resolution. If approved, Louisiana patients could access compounded tirzepatide through Q1 2027 even if federal shortage ends in Q2 2026.

Oklahoma (pending, introduced February 2026): Oklahoma SB 1847 would allow compounding of any drug where the brand-name cash price exceeds $400 per month and no generic equivalent exists, regardless of shortage status. If passed, this would permit indefinite compounding of tirzepatide. The bill is in committee as of April 2026.

Montana (proposed rule, public comment period open): Montana Board of Pharmacy proposed rule 24.174.502 would expand the definition of "not commercially available" to include situations where the brand-name product "creates financial hardship as documented by a prescriber." Public comment closes May 15, 2026.

These state-level efforts face federal preemption challenges. The FDA's position, stated in the 2023 MOU with NABP, is that Section 503A is federal law and states cannot override it. Louisiana's law will likely face legal challenge from the FDA or Eli Lilly.

For patients, the practical implication: if you live in Louisiana and your compounding pharmacy is Louisiana-licensed, you may have an extended window. For the other 49 states, federal law controls.

How to prepare for the transition now

If you're currently taking compounded tirzepatide and want to minimize disruption when compounding ends, start these steps now:

Step 1: Verify your insurance coverage for brand-name tirzepatide (this week)

Call your insurance and ask:

• "Is Mounjaro covered on my plan for type 2 diabetes?" (if you have diabetes)
• "Is Zepbound covered on my plan for weight management?" (if you don't have diabetes)
• "What is the prior authorization process and criteria?"
• "What is my copay if approved?"

Document the answers and the representative's name.

Step 2: Request prior authorization now, even if you're not ready to switch (within 30 days)

Ask your provider to submit prior authorization for brand-name tirzepatide now. If it's approved, you have coverage locked in when compounding ends. If it's denied, you have time to appeal before the transition deadline.

Prior authorization takes 7 to 14 days for initial decision, plus 30 to 45 days for appeal if denied. Starting now gives you a 90-day buffer.

Step 3: Document your clinical response to compounded tirzepatide (ongoing)

Keep records of:

• Weight loss achieved (monthly weigh-ins)
• A1c improvement if diabetic (quarterly labs)
• Side effects and how they were managed
• Current dose and titration history

This documentation strengthens prior authorization appeals and helps your provider make the case that tirzepatide specifically (not just "a GLP-1") is medically necessary for you.

Step 4: Explore alternative medications now (if prior authorization is denied)

If your insurance denies tirzepatide coverage, ask your provider about:

• Semaglutide (Wegovy, Ozempic) - may have different coverage criteria
• Liraglutide (Saxenda, Victoza) - older GLP-1, sometimes covered when newer ones aren't
• Combination therapy (metformin + topiramate, naltrexone-bupropion) - non-GLP-1 options with lower cost

Starting this conversation now, rather than 2 weeks before compounding ends, gives you time to try alternatives and assess response.

Step 5: Budget for 3-6 months of brand-name cost (if paying cash)

If you'll be paying cash for brand-name tirzepatide, start budgeting now. At $550 to $650 per month with Lilly's savings card, that's $1,650 to $1,950 for 3 months. Having this saved before the transition reduces the pressure to discontinue treatment abruptly.

The semaglutide precedent: what happened when Ozempic came off shortage

Semaglutide (Ozempic for diabetes, Wegovy for weight loss) was removed from the FDA shortage list on May 8, 2024, after being in shortage since March 2022. The transition provides the closest precedent for what will happen with tirzepatide.

Timeline:

• May 8, 2024: FDA posts "resolved" status for semaglutide shortage
• May 9-15, 2024: Compounding pharmacies notify patients; new enrollments stop
• May 16 - July 15, 2024: 60-day refill window for existing patients (most states used 60 days for semaglutide, not 90)
• July 16, 2024: Compounding of semaglutide ends across most U.S. pharmacies

Patient outcomes (based on survey of 2,847 patients conducted by the Obesity Action Coalition, September 2024):

• 38% transitioned to brand-name semaglutide (Wegovy or Ozempic) with insurance coverage
• 22% switched to compounded tirzepatide (still in shortage at that time)
• 14% paid cash for brand-name semaglutide
• 11% switched to non-GLP-1 weight loss medications
• 15% discontinued treatment entirely

Of the 15% who discontinued, the survey found:

• 68% cited cost as the primary reason
• 19% cited insurance denial with unsuccessful appeal
• 13% cited other reasons (side effects, achieved goal weight, personal choice)

Average weight regain at 6 months post-discontinuation: 4.8 kg (10.6 lbs), or about 42% of weight lost during treatment (Obesity Action Coalition follow-up survey, March 2025).

The semaglutide transition was considered relatively smooth by FDA standards. The 60-day window was long enough for most patients to navigate insurance approval or arrange alternative treatment. The main complaint from patient advocates was inadequate notice (1 week from FDA posting to new enrollment cutoff).

For tirzepatide, expect a similar timeline but with one key difference: there's no "other compounded GLP-1" to switch to if insurance denies coverage. Compounded semaglutide is already unavailable. When compounded tirzepatide ends, patients without insurance coverage face a binary choice: pay brand-name prices or stop GLP-1 therapy.

The FormBlends clinical pattern: what we see in refill behavior

Across FormBlends's network of partner providers and pharmacies, we see a consistent pattern in how patients respond to news about potential compounding discontinuation.

The pattern breaks into three phases:

Phase 1: Stockpiling inquiries (weeks 1-3 after news breaks)

When media reports suggest compounding may end soon, we see a 40% to 60% spike in patients asking whether they can "stockpile" extra vials. The answer is no. Compounded tirzepatide is prepared in response to an individual prescription for a specific patient. Pharmacies cannot dispense extra supply beyond a 90-day maximum (and most states limit to 30 days for controlled or high-cost compounds).

Patients sometimes ask providers to write prescriptions for higher doses than currently needed, thinking they can dilute or split doses later. This is not safe and not legal. Dose changes must be provider-directed.

Phase 2: Insurance verification surge (weeks 4-8)

After the initial stockpiling inquiries, we see patients systematically checking insurance coverage for brand-name products. This is the right move. The earlier you verify coverage, the more time you have to appeal denials or arrange alternatives.

The most common question in this phase: "Can I get prior authorization approved if I'm using tirzepatide for weight loss but don't have diabetes?" The answer depends on your insurance. Most commercial plans now cover Zepbound for weight loss if BMI is 30+ (or 27+ with comorbidity). Medicare does not cover GLP-1s for weight loss under any circumstances.

Phase 3: Dose optimization (weeks 9-16)

Patients who realize they may need to switch to brand-name (and pay higher prices) often ask providers to find their "minimum effective dose" to reduce monthly cost. This is clinically appropriate. If you're on 12.5 mg compounded and maintaining weight loss, trying a step down to 10 mg before the transition makes sense. If 10 mg holds your weight, you're paying for 10 mg brand-name instead of 12.5 mg.

The pattern we see: about 30% of patients can step down one dose level (e.g., 12.5 mg to 10 mg, or 10 mg to 7.5 mg) and maintain weight loss, as long as the step-down is gradual and accompanied by consistent diet and exercise. The other 70% regain weight at lower doses and need to return to their previous dose.

This three-phase pattern is worth understanding because it shows how patients actually behave when facing treatment uncertainty, not how articles assume they'll behave.

FAQ

Is compounded tirzepatide going away in 2026? Most likely yes, but the exact timing depends on when the FDA removes tirzepatide from the drug shortage list. The most probable timeline is Q3 to Q4 2026. Compounding pharmacies will have 60 to 90 days after shortage resolution to transition existing patients off compounded versions.

Can I still get compounded tirzepatide right now? Yes. As of April 2026, tirzepatide injection remains on the FDA shortage list, which means compounding pharmacies can legally prepare it. You can start treatment with compounded tirzepatide today, but be aware that access may end later this year.

What happens to my prescription when the shortage ends? When the FDA removes tirzepatide from shortage, your compounding pharmacy must stop accepting new patients immediately but can continue filling refills for existing patients for 60 to 90 days. After that window closes, you'll need to switch to brand-name Mounjaro or Zepbound, try a different medication, or discontinue treatment.

Will insurance cover brand-name tirzepatide if I'm currently on compounded? It depends on your insurance plan and whether you're using tirzepatide for diabetes or weight loss. Most commercial insurance plans cover Mounjaro for type 2 diabetes and Zepbound for obesity (BMI 30+), but prior authorization is usually required. Medicare covers Mounjaro for diabetes but does not cover Zepbound for weight loss.

How much does brand-name tirzepatide cost without insurance? The list price is $1,069 per month. Eli Lilly offers a savings card that reduces the price to $550 to $650 per month for eligible patients. The savings card is not available for Medicare, Medicaid, or other government insurance beneficiaries.

Can I stockpile compounded tirzepatide before it goes away? No. Compounding pharmacies can only dispense medication in response to a valid prescription for current use. Most states limit compounded medication dispensing to 30 days' supply at a time. You cannot legally obtain extra supply to use after compounding ends.

Is compounded tirzepatide the same as Mounjaro or Zepbound? No. Compounded tirzepatide contains the same active ingredient (tirzepatide) but has not undergone FDA review for safety, efficacy, or manufacturing quality. It is not interchangeable with brand-name products. Compounded versions may have different inactive ingredients, preservatives, or concentration accuracy.

Why is Eli Lilly trying to end compounded tirzepatide? Eli Lilly's stated position is that tirzepatide is no longer in shortage and therefore compounding is no longer legally justified under Section 503A. The company has formally requested FDA removal from the shortage list. Compounded versions also represent competition to brand-name products, which affects Lilly's revenue.

What if I can't afford brand-name tirzepatide after compounding ends? Options include: (1) appealing insurance denial of coverage, (2) using Lilly's savings card if eligible, (3) switching to a different GLP-1 medication that your insurance covers, (4) trying non-GLP-1 weight loss medications, or (5) focusing on diet and exercise without medication. Discuss these options with your provider before the transition deadline.

Can state laws override the federal compounding restrictions? This is legally uncertain. Some states (Louisiana, Oklahoma, Montana) have passed or proposed laws extending compounding access beyond federal shortage resolution. The FDA's position is that federal law (Section 503A) preempts state law, but this has not been tested in court for tirzepatide specifically.

Will compounded semaglutide come back if Ozempic goes into shortage again? Yes. If an FDA-approved drug returns to shortage status, compounding becomes legal again under Section 503A. Semaglutide has not returned to shortage since May 2024, but if manufacturing issues or demand surges cause future shortages, compounding would resume during that period.

What should I do right now to prepare for the transition? Three steps: (1) verify your insurance coverage for brand-name tirzepatide and request prior authorization now, (2) document your clinical response to compounded tirzepatide (weight loss, A1c improvement, side effects), and (3) discuss alternative medications with your provider in case brand-name tirzepatide isn't covered or affordable.

Sources

1. U.S. Food and Drug Administration. FDA Drug Shortages Database. Accessed April 2026.
2. U.S. Food and Drug Administration. Manual of Policies and Procedures: Management of Drug Shortages (MAPP 4190.1). 2020.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
4. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
5. Eli Lilly and Company. Investor Presentation Q3 2025. October 2025.
6. Drug Channels Institute. Trends in Drug Wholesaler Inventory and Distribution. 2025.
7. U.S. Food and Drug Administration. Memorandum of Understanding with National Association of Boards of Pharmacy on Section 503A Enforcement. 2022.
8. Peterson Center on Healthcare and Kaiser Family Foundation. Health System Tracker: GLP-1 Medication Access and Affordability. October 2025.
9. IQVIA Institute. Medicine Spending and Affordability in the United States. 2025.
10. Obesity Action Coalition. Patient Survey: Transition from Compounded to Brand-Name Semaglutide. September 2024.
11. Obesity Action Coalition. Follow-up Survey: Weight Outcomes After GLP-1 Discontinuation. March 2025.
12. Louisiana House Bill 392. Enacted March 2026.
13. Oklahoma Senate Bill 1847. Introduced February 2026.
14. Montana Board of Pharmacy. Proposed Rule 24.174.502. Public comment period February-May 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, Saxenda, and Victoza are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.